Inotek Pharmaceuticals Secures $21,000,000 New Funding

  • Feed Type
  • Date
    9/27/2013
  • Company Name
    Inotek Pharmaceuticals
  • Mailing Address
    131 Hartwell Ave Lexington, MA 02421
  • Company Description
    Inotek Pharmaceuticals Corporation is a private, high-growth, development-stage pharmaceutical company founded in 1996. The Company has leveraged its small molecule chemistry expertise to discover and develop a deep pipeline of therapeutics targeting cell death, DNA repair and inflammatory pathways.
  • Website
    http://www.inotekcorp.com
  • Transaction Type
    Debt, Venture Equity
  • Transaction Amount
    $21,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds from this financing will be used to advance Inotek’s lead product, trabodenoson, a novel eye drop that increases aqueous fluid outflow via the eye’s trabecular meshwork, through Phase 2 studies in glaucoma.
  • M&A Terms
  • Venture Investor
    Devon Park Bioventures
  • Venture Investor
    Rho Ventures
  • Venture Investor
    Care Capital
  • Venture Investor
    MedImmune Ventures
  • Venture Investor
    Pitango Venture Capital
  • Venture Investor
    Horizon Technology Finance

By posting a comment, you agree to our terms and conditions.